| Biogen–Cevec: cell line technology, 202101– license €na to Elevecta technology for manufacutring of AAV vectors for gene therapies |
2021-01-08 |
| AmpTec–Merck (DE): investment, 202101 acquisition €na of AmpTec GmbH bei Merck |
2021-01-07 |
| BioGeneration Ventures–EU (govt): investment, 202101 final closing of BGV IV totalling €140m incl investor European Investment Fund |
2021-01-07 |
| BioGeneration Ventures–Germany (govt): investment, 202101 final closing of BGV IV totalling €140m incl investor KfW Capital |
2021-01-07 |
| BioGeneration Ventures–SEVERAL: investment, 202101 final closing of BGV IV with €140m incl Lilly + Novo Ventures + BMS + Schroder Adveq et al |
2021-01-07 |
| Cellectis–Sirion Biotech: cell/gene therapy manufacturing technology, 202101– non-excl license €na to LentiBoost technology for CAR-T cell therapies |
2021-01-07 |
| Sterna Biologicals–SEVERAL: investment, 202101 financing round Series A 2nd closing €10m bringing total Series A to €22m |
2021-01-07 |
| Adeptrix–Bruker: investment, 202101 financing round Series A incl new + minority investor Bruker Corp |
2021-01-06 |
| Adeptrix–SEVERAL: investment, 202101 financing round Series A closed with new + minority investor Bruker Corp |
2021-01-06 |
| Eleva–Zukunftsfonds Heilbronn: investment, 202101– up to €60m for development of CPV-101 |
2021-01-06 |
| Novasep–Sartorius: investment, 202101– acquisition €na of Novasep’s chromatography process equipment division by Sartorius ANNOUNCED |
2021-01-06 |
| Senti Biosciences–Bayer: investment, 202101 financing round Series B totalling $105m incl new + lead investor Leaps by Bayer |
2021-01-06 |
| Senti Biosciences–SEVERAL: investment, 202101 financing round Series B $105m led by Leaps by Bayer |
2021-01-06 |
| Terns Pharmaceuticals–Samsara Capital: investment, 202101 financing round Series C totalling $87m incl co-investor Samsara Capital |
2021-01-05 |
| Terns Pharmaceuticals–SEVERAL: investment, 202101 financing round Series C $87m led by Deerfield Management |
2021-01-05 |
| Arvelle Therapeutics–Angelini: investment, 202101– acquisition merger up to $960m in cash with $610m after approval of cenobamate + $350m milestones |
2021-01-04 |
| Somatex Medical Technologies–Hologic: investment, 202101 acquisition $64m of Somatex by Hologic |
2021-01-04 |
| Biosun Biochemicals–BRAIN Biotech: investment, 202101 acquisition 100% €na by BRAIN AG |
2021-01-01 |
| Cutanos–Max Planck: topical drug delivery technology, 202101– license excl to LC-TDS technology from Max Planck Innovation |
2021-01-01 |
| Qiagen–Wellcome Trust: COSMIC Database, 202101– distribution excl rights to license + distribute COSMIC for commercial use |
2021-01-01 |
| Cajal Neuroscience–Evotec: investment, 202012 existent Evotec owns 1.82% of voting rights |
2020-12-31 |
| Dark Blue Therapeutics–Evotec: investment, 202012 existent Evotec owns 18.67% of voting rights |
2020-12-31 |
| Mission BioCapital–Evotec: investment, 202012 existent Evotec owns 7.22% of voting rights of Mission BioCapital V LP |
2020-12-31 |
| NephThera–Evotec: investment, 202012 existent Evotec owns 50.00% of voting rights |
2020-12-31 |
| SomaLogic–Novartis: investment, 202012 financing round Series A 2nd closing totalling addit $81m incl Novartis |
2020-12-22 |
| SomaLogic–SEVERAL: investment, 202012 financing round Series A 2nd closing additional $81m bringing total Series A to $204m or $214m |
2020-12-22 |
| Evotec–Alloy Therapeutics: transgenic mouse technolgy, 202012– supply access to ATX-Gx platform to expand Evotec antibody discovery platform |
2020-12-21 |
| Peptilogics–Angermayer Group: investment, 202012 financing round Series B totalling $35.4m incl new + lead investor Presight Capital |
2020-12-21 |
| Peptilogics–SEVERAL: investment, 202012 financing round Series B $35.4m led by Presight Capital |
2020-12-21 |
| Cadent Therapeutics–Novartis: investment, 202012– acquisition $210m upfront + $560m milestones ANNOUNCED |
2020-12-17 |
| ECBF–SEVERAL: investment, 202012–202202 raising of additional €125m + final closing of fund at €300m |
2020-12-16 |
| Exo Therapeutics–Novartis: investment, 202012 financing round Series A totalling $25m incl investor Novartis Venture Fund |
2020-12-16 |
| Exo Therapeutics–SEVERAL: investment, 202012 financing round Series A $25m incl Newpath Partners + NVF + CRV + 6 Dimensions Capital |
2020-12-16 |
| Neuron23–SEVERAL: investment, 202012 financing round Series B $80m led by new investor Redmile Group |
2020-12-16 |
| ECBF–Neste: investment, 202012 2nd closing with additional sum totalling €93m incl new investor Neste |
2020-12-15 |
| ECBF–Nestlé: investment, 202012 2nd closing with additional sum totalling €93m incl new investor Nestlé |
2020-12-15 |
| ECBF–Nordrhein-Westfalen (govt): investment, 202012 2nd closing with additional sum totalling €93m incl new investor NRW.Bank |
2020-12-15 |
| ECBF–OTHER: investment, 202012 2nd closing with additional sum totalling €93m incl undisclosed family office as new investor |
2020-12-15 |
| ECBF–SEVERAL: investment, 202012 2nd closing with additional €93m from new investors bringing total to €175m |
2020-12-15 |
| ECBF–Volkswohl Bund: investment, 202012 2nd closing with additional sum totalling €93m incl new investor Volkswohl Bund Versicherungen |
2020-12-15 |
| MYR GmbH–Gilead: investment, 202012 acquisition €1.15b in cash + €300m milestones of MYR GmbH by Gilead Sciences Inc |
2020-12-10 |
| NBE Therapeutics–Boehringer: investment, 202012– acquisition up to €1.18b by Boehringer |
2020-12-10 |
| Resolve Biosciences–Alafi Capital: investment, 202012 financing round Series A totalling $24m incl co-investor Alafi Capital |
2020-12-10 |
| Resolve Biosciences–Bioscribe: public relations, 202012 service existent by Bioscribe |
2020-12-10 |
| Resolve Biosciences–High-Tech Gründerfonds: investment, 202012 financing round Series A totalling $24m incl co-investor HTGF |
2020-12-10 |
| Resolve Biosciences–MasterMind Advisory Services: investment, 202012 financing round Series A totalling $24m incl co-lead investor MasterMind |
2020-12-10 |
| Resolve Biosciences–PERSON: investment, 202012 financing round Series A totalling $24m incl co-investor John Shoffner |
2020-12-10 |
| Resolve Biosciences–PS Capital Management: investment, 202012 financing round Series A totalling $24m incl co-lead investor PS Capital |
2020-12-10 |
| Resolve Biosciences–SEVERAL: investment, 202012 financing round Series A $24m co-led by PS Capital Management + MasterMind Advisory Services |
2020-12-10 |
| Curexsys–Evotec: investment, 202012 seed financing round totalling €8.2m incl Evotec acquiring 37% equity stake |
2020-12-09 |
| Curexsys–Sartorius: investment, 202012 seed financing round totalling €8.2m incl Sartorius acquiring 21% equity stake |
2020-12-09 |
| Curexsys–SEVERAL: investment, 202012 seed financing round €8.2m led by Evotec + Sartorius |
2020-12-09 |
| Novartis–RetinAI Medical: AI-based image analysis, 202012– collab expansion master agreement using RetinAI Discovery platform in ophthalmology |
2020-12-08 |
| RetinAI Medical–Charles Consultants: public relations, 202012 service existent by Sue Charles |
2020-12-08 |
| Biomes NGS–GPS Ventures: investment, 202012 pre-series A investment €2m from GPS Ventures GmbH |
2020-12-07 |
| Boehringer–Proxygen: molecular glue degraders, 202012– collab + license agreem developm in combi with PROTACs against oncogenic targets |
2020-12-07 |
| Mosa Meat–SEVERAL: investment, 202012 financing round Series B 2nd closing $20m bringing total Series B to $75m |
2020-12-07 |
| Bayer–Atara Biotherapeutics: cell therapy, 202012–202209 collab + ww license $60m upfront + $610m milestones CAR T-cell therapies TERMINATED 9/22 |
2020-12-06 |
| MaaT Pharma–Céleste Management: investment, 202012 financing round Series B extension totalling €7.35m incl new + co-investor Céleste Management |
2020-12-01 |
| MaaT Pharma–SEVERAL: investment, 202012 financing round Series B extension €7.35m led by Bpifrance bringing total Series B to €25.35m |
2020-12-01 |
| MaaT Pharma–SkyViews Life Science: investment, 202012 financing round Series B extension totalling €7.35m incl new + co-investor SkyViews Life Science |
2020-12-01 |
| Noema Pharma–SEVERAL: investment, 202012 financing round Series A CHF54m ($59m) co-led by Sofinnova Partners + Polaris Partners |
2020-12-01 |
| Slack Technologies–Salesforce: investment, 202012– acquisition $27.7b in cash + shares of Slack by Salesforce ANNOUNCED |
2020-12-01 |
| Adrenomed–HBM: investment, 202011 financing round Series E totalling €22.2m incl existing + co-lead investor HBM Healthcare Investments |
2020-11-30 |
| Adrenomed–SEVERAL: investment, 202011 financing round Series E €22.2m co-led by Wellington Partners + HBM |
2020-11-30 |
| Adrenomed–Wellington Partners: investment, 202011 financing round Series E totalling €22.2m incl existing + co-lead investor Wellington Partners |
2020-11-30 |
| Perfood–Boehringer: investment, 202011 financing round Series A totalling €5m incl lead investor Boehringer Ingelheim Venture Fund |
2020-11-30 |
| Perfood–SEVERAL: investment, 202011 financing round Series A €5m led by Boehringer Ingelheim Venture Fund |
2020-11-30 |
| Perfood–UV-Cap: investment, 202011 financing round Series A totalling €5m incl co-investor UV-Cap |
2020-11-30 |
| Perfood–Verve Capital Partners: investment, 202011 financing round Series A totalling €5m incl co-investor investiere |
2020-11-30 |
| Kadans Science Partner–Axa: investment, 202011–202012 acquisition €500m by Axa IM Real Assets on behalf of clients from Oaktree Capital Management |
2020-11-26 |
| BioNTech–InstaDeep: AI-based drug discovery, 2019– collab initiated in 2019 |
2020-11-25 |
| BioNTech–InstaDeep: AI-based drug discovery, 202011– strategic collab incl joined AI Innovation Lab to develop immunotherapies |
2020-11-25 |
| Emergence Therapeutics–High-Tech Gründerfonds: investment, 202011 follow-on seed financing round incl lead investor HTGF |
2020-11-25 |
| Emergence Therapeutics–SEVERAL: investment, 202011 follow-on seed financing round led by HTGF |
2020-11-25 |
| Innatera Nanosystems–btov Partners: investment, 202011 seed financing round totalling €5m incl co-lead investor btov Industrial Technologies Fund |
2020-11-25 |
| Innatera Nanosystems–MIG Fonds: investment, 202011 seed financing round totalling €5m incl co-lead investor MIG Verwaltungs AG |
2020-11-25 |
| Innatera Nanosystems–SEVERAL: investment, 202011 seed financing round €5m co-lead by MIG Verwaltungs AG + btov Industrial Technologies Fund |
2020-11-25 |
| Emphysys–Paramit: investment, 202011 acquisition of Emphysis Inc by Paramit Corp |
2020-11-24 |
| Atai Life Sciences–SEVERAL: investment, 202011 financing round Series C $125m incl $32m converted debt co-led by Apeiron + Peter Thiel + Catalio |
2020-11-23 |
| Voluntis–Debiopharm: investment, 202011 capital increase totalling €5.93m incl €3.92m from new + lead investor Debiopharm Innovation Fund |
2020-11-23 |
| Voluntis–Indigo (Eric Carreel): investment, 202011 capital increase totalling €5.93m incl €1m from existing + co-investor Indigo |
2020-11-23 |
| Voluntis–SEVERAL: investment, 202011 capital increase €5.93m net €5.7m led by Debiopharm Innovation Fund |
2020-11-23 |
| Relief Therapeutics–GEM Global Yield: investment, 202011 existent majority shareholder owning 51.38% of capital + voting rights |
2020-11-19 |
| SynOx Therapeutics–Roche: emactuzumab, 202011 excl ww rights for developm + production + commercialisation |
2020-11-19 |
| SynOx Therapeutics–SEVERAL: investment, 202011 financing round Series A €37m co-led by HealthCap + Medicxi with Forbion + Gimv |
2020-11-19 |
| Pharvaris–Bain Capital: investment, 202011 financing round Series C totalling $80m incl existing + co-investor Bain Capital Life Sciences |
2020-11-18 |
| Pharvaris–Cormorant Asset Management: investment, 202011 financing round Series C totalling $80m incl new + co-investor Cormorant Asset Management |
2020-11-18 |
| Pharvaris–Foresite Capital: investment, 202011 financing round Series C totalling $80m incl existing + co-investor Foresite Capital |
2020-11-18 |
| Pharvaris–General Atlantic: investment, 202011 financing round Series C totalling $80m incl new + co-lead investor General Atlantic |
2020-11-18 |
| Pharvaris–Rockefeller: investment, 202011 financing round Series C totalling $80m incl existing + co-investor Venrock Health Capital Partners |
2020-11-18 |
| Pharvaris–SEVERAL: investment, 202011 financing round Series C $80m co-led by Viking Global Investors + General Atlantic |
2020-11-18 |
| Pharvaris–VenBio: investment, 202011 financing round Series C totalling $80m incl existing + co-investor venBio Partners |
2020-11-18 |
| Pharvaris–Viking Global Investors: investment, 202011 financing round Series C totalling $80m incl new + co-lead investor Viking Global Investors |
2020-11-18 |
| Roche–Lead Pharma: small-molecule immuno modulators, 202011– collab + license agreem up to €260m incl €10m upfront plus royalties |
2020-11-16 |
| Start Codon–Novartis: investment, 202011 closing of Start Codon Fund I LP totalling £15m incl LP Novartis International AG |
2020-11-16 |
| Start Codon–SEVERAL: investment, 202011 closing of Start Codon Fund I LP at £15m incl LPs Novartis International AG + Cambridge Innovation Capital |
2020-11-16 |
| m2p-labs–Danaher: investment, 202011 acquisition of m2p-biolabs by Beckman Coulter Life Sciences |
2020-11-12 |
| Metagenomi–Agent Capital: investment, 202011 financing round Series A totalling $65m incl co-investor Agent Capital |
2020-11-12 |
| Metagenomi–Bayer: investment, 202011 financing round Series A totalling $65m incl co-lead investor Leaps by Bayer |
2020-11-12 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
![Picture [iito] Life Science Business Portals Media Data 2022 2 650x100px](/banner/iito-business-intelligence-20220406-650-100-promote-brand-to-decision-makers.jpg)
1 2 3 ... 8 9 10 ... 36 37 38 
Date![Picture [iito] Männer Ballett 650x100px](/banner/iito-business-intelligence-20211013-650-100-summer-banner-series-maenner-ballett.jpg)
![Picture [iito] [LSE] Life-Sciences-Europe.com Business Portal 650x300px](/banner/iito-business-intelligence-20220406-650-300-lse-life-sciences-europe.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
